Literature DB >> 1534854

Adenovirus E1A makes two distinct contacts with the retinoblastoma protein.

N Dyson1, P Guida, C McCall, E Harlow.   

Abstract

Two regions near the amino terminus of the adenovirus E1A protein, which were first identified by sequence conservation among various adenovirus serotypes, have been shown by genetic studies to be essential for E1A-mediated transformation. These same regions are also required for interaction with a number of cellular proteins, including the retinoblastoma protein (pRB). Using synthetic peptides corresponding to portions of these conserved regions, we show that each region can bind independently to pRB. These interactions were observed in both competition and binding assays. In both types of assay, region 2 peptides (E1A amino acids 115 to 132) bound pRB with higher affinity than did region 1 peptides (E1A amino acids 37 to 54), while a peptide combining region 1 and 2 sequences consistently provided the highest-affinity interaction. Cross-blocking experiments using region 1 peptides and region 2 peptides suggested that these two regions of E1A make distinct contacts with pRB. These data support the notion that the pRB-binding domain of E1A contains at least two functional elements.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1534854      PMCID: PMC241277     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Cellular targets for transformation by the adenovirus E1A proteins.

Authors:  P Whyte; N M Williamson; E Harlow
Journal:  Cell       Date:  1989-01-13       Impact factor: 41.582

2.  Synthetic peptide substrates for casein kinase II.

Authors:  D R Marshak; D Carroll
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

3.  Association of adenovirus early-region 1A proteins with cellular polypeptides.

Authors:  E Harlow; P Whyte; B R Franza; C Schley
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

4.  Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product.

Authors:  W G Kaelin; M E Ewen; D M Livingston
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

5.  Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes.

Authors:  E Moran; B Zerler; T M Harrison; M B Mathews
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

6.  Mapping of cellular protein-binding sites on the products of early-region 1A of human adenovirus type 5.

Authors:  C Egan; T N Jelsma; J A Howe; S T Bayley; B Ferguson; P E Branton
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

7.  A point mutational analysis of human papillomavirus type 16 E7 protein.

Authors:  C Edmonds; K H Vousden
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

8.  Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B.

Authors:  J Pines; T Hunter
Journal:  Nature       Date:  1990-08-23       Impact factor: 49.962

9.  Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis.

Authors:  J A Howe; J S Mymryk; C Egan; P E Branton; S T Bayley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

10.  An N-terminal transformation-governing sequence of SV40 large T antigen contributes to the binding of both p110Rb and a second cellular protein, p120.

Authors:  M E Ewen; J W Ludlow; E Marsilio; J A DeCaprio; R C Millikan; S H Cheng; E Paucha; D M Livingston
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

View more
  41 in total

1.  Mutagenesis of the pRB pocket reveals that cell cycle arrest functions are separable from binding to viral oncoproteins.

Authors:  F A Dick; E Sailhamer; N J Dyson
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7.

Authors:  S L Gonzalez; M Stremlau; X He; J R Basile; K Münger
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Role of the LXCXE binding site in Rb function.

Authors:  A Dahiya; M R Gavin; R X Luo; D C Dean
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins.

Authors:  N Dyson; P Guida; K Münger; E Harlow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins.

Authors:  A V Samuelson; S W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

6.  Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor.

Authors:  Xin Liu; Ronen Marmorstein
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

7.  pRB-E2F1 complexes are resistant to adenovirus E1A-mediated disruption.

Authors:  L A Seifried; S Talluri; M Cecchini; L M Julian; J S Mymryk; F A Dick
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

8.  A cellular repressor of E1A-stimulated genes that inhibits activation by E2F.

Authors:  E Veal; M Eisenstein; Z H Tseng; G Gill
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  E2F1 and E1A(12S) have a homologous activation domain regulated by RB and CBP.

Authors:  D Trouche; T Kouzarides
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

10.  Coevolution of persistently infecting small DNA viruses and their hosts linked to host-interactive regulatory domains.

Authors:  F F Shadan; L P Villarreal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.